Press Releases

MiraDx Announces New Study Published in Clinical Cancer Research Validating PROSTOX™ ultra Diagnostic Test for Predicting Radiation-Induced Late Toxicity in Prostate Cancer

A groundbreaking study published in the journal Clinical Cancer Research validates previous findings that the PROSTOX ultra test can predict long-term side effects from radiation therapy for prostate cancer, prior to starting treatment. Led by researchers at UCLA’s Department of Radiation Oncology, the study confirms the effectiveness of PROSTOX ultra, the first test capable of predicting long-term radiation side effects based on a patient’s unique genetic profile. The findings reinforce that radiation toxicity is a biologically unique response for each patient, underscoring the potential to personalize and improve cancer treatment using genetics.

Clearwater Publishes Cyber Risk Benchmark Trend Report for Healthcare Vulnerability Management

Association for Molecular Pathology Celebrates U.S. District Court’s Decision to Vacate FDA Rule on Laboratory-Developed Test Procedure Regulation

AMP announced a favorable ruling in its lawsuit against the U.S. FDA over the regulation of laboratory-developed test procedures.

CluePoints Appoints Usama Dar as Chief Product and Technology Officer

CluePoints, provider of leading statistical and AI-driven software solutions, has today announced Usama Dar as its new Chief Product and Technology Officer.

Andaman7 Seeks $5m to Continue Investment in Pioneering Technology

Andaman7, the platform transforming healthcare communications and bridging the gap between patients and researchers, is seeking investment to reach the next milestones in its ground-breaking journey.

Baylor Genetics Presents New Data on Genetic and Functional Testing to Diagnose Mitochondrial Disorders at 2025 ACMG Annual Clinical Genetics Meeting

Baylor Genetics Presents New Data on Genetic and Functional Testing to Diagnose Mitochondrial Disorders at 2025 ACMG Annual Clinical Genetics Meeting

Novartis Strengthens Cardiovascular Portfolio with $3.08 Billion Anthos Therapeutics Acquisition

Anthos Therapeutics, Inc., a business that produces abelacimab (full human monoclonal antibody), a late-stage medication being developed to prevent stroke and systemic embolism in patients with atrial fibrillation, has agreed to be acquired by Novartis. Upon concluding the deal, Novartis will pay $925 million upfront, subject to certain usual adjustments. If certain sales and regulatory milestones are met, Novartis may also pay an additional $2.15 billion.

Coronado Research Announce the Appointment of Gary Lyons as EVP Medical Affairs

Coronado Research has appointed Gary Lyons as EVP Medical Affairs. Gary is a seasoned senior Medical Affairs leader with extensive strategic and operational implementation experience across the industry and product lifecycle.

Proscia Raises $50M To Advance AI-Driven Pathology And Deliver The Future Of Precision Medicine

Funding led by global software investor Insight Partners comes as the surge in cancer cases compounds the impact of the shrinking pathologist workforce.

DIASORIN LAUNCHES THE SIMPLEXA™ C. AURIS DIRECT ASSAY ON THE LIAISON® MDXv INSTRUMENT IN ALL COUNTRIES ACCEPTING THE CE MARK

Diasorin announced the availability of its Simplexa C. Auris Direct kit in all countries accepting the CE mark. The targeted molecular diagnostic test is performed on the LIAISON MDX instrument, yielding patient results in less than two hours.

Clearwater Joins CancerX to Help Drive Strong Cybersecurity and Data Privacy Practices in the Fight Against Cancer

START Further Expands Its Global Oncology Site Network with the Addition of Carolina Urologic Research Center

START's site network solidifies its global leadership in urological cancer trials.

Coronado Research Announce the Appointment of Nick Littlebury as EVP, Regulatory Affairs

Coronado Research has appointed Nick Littlebury as EVP, Regulatory Affairs. Nick is a senior regulatory leader with extensive strategic and operational experience across the pharmaceutical industry's product lifecycle.

Baylor Genetics to Showcase Genetic Testing Innovations for Rare Disease at ACMG 2025 Annual Clinical Genetics Meeting

As Baylor Genetics celebrates a decade of leadership at the forefront of genetic testing, it is set to exhibit its latest scientific studies in genetic testing at the 2025 ACMG Annual Clinical Genetics Meeting, taking place March 18-22, 2025, in Los Angeles, CA. The Company will be located at Booth #217 at the Los Angeles Convention Center.

Clearwater Publishes First-of-its-Kind Report Examining Cybersecurity Performance of Private Equity-Backed Portfolio Companies in Healthcare

ClearNote Health’s Avantect® Pancreatic Cancer Test Now Available to Health Plan Members Accessing Claritev’s National PPO Networks

ClearNote Health announced an agreement with Claritev, Inc., (previously MultiPlan, Inc.) that will make ClearNote Health’s Avantect Pancreatic Cancer Test available to health plan members accessing Claritev’s national PHCS and MultiPlan Networks.

Augurex Announces UK Conformity Assessed (UKCA) Authorization for JOINTstat®, Expanding Access to Cutting-Edge Rheumatoid Arthritis Testing in Great Britain

Augurex has received UK Conformity Assessed marking for JOINTstat®, authorizing its use in Great Britain for rheumatoid arthritis diagnosis and management. JOINTstat® is a well-established rheumatoid arthritis blood test in North America, approved by Health Canada and available in the U.S. as a laboratory-developed test.

IQVIA Laboratories launches Site Lab Navigator with breakthrough e-Requisition innovation to transform clinical trials

IQVIA Laboratories is introducing its Site Lab Navigator, an advanced suite of solutions that automates and streamlines lab workflows for clinical trial sponsors and investigator sites, aiming to significantly reduce administrative burden on sites and improve the quality and execution of trials.

Mural Health and ICON Announce Partnership to Enhance Participant and Site Experience in Clinical Trials

Mural Health Technologies, Inc., a patient-first clinical trial technology company, and ICON plc (NASDAQ: ICLR), a global healthcare intelligence and clinical research organization, today announce a partnership to utilize the participant management and payments platform, Mural Link.

Owkin Launches ATLANTIS: An Extensive Multimodal Patient Data Discovery Program Across 7 Countries in 11 Therapeutic Areas

Owkin, a pioneer in Agentic AI for decoding the complexities of biology, has launched a comprehensive multimodal patient data discovery program to accelerate multimodal data access and advance medical research.